Pharma News

China is expected to have over 800,000 lung cancer patients diagnosed annually by 2020, with nearly 700,000 people dying from the disease each year, a media report said on Tuesday.

Researchers from Johns Hopkins University have developed a method to efficiently turn human stem cells into retinal nerve cells that transmit visual signals from the eye to the brain.

Researchers at the Stanford University School of Medicine have identified a gene involved in the control of sleep that, when working properly, appears to reduce the risk of heart failure and improve treatment outcome, says a study.

Researchers have developed a new, more precise way to control the differentiation of stem cells into bone cells which shows promise for bone regeneration, growth and healing.

Pfizer Inc. announced top-line results of a Phase 3 study evaluating the efficacy and safety of LYRICA (pregabalin) Capsules CV in adults with chronic post-traumatic peripheral neuropathic pain. The study did not meet its primary efficacy endpoint.

Insights from experts working on-the-ground in lung cancer, compiled by Boehringer Ingelheim, shed light on challenges faced by patients with advanced stage adenocarcinoma, a type of non-small cell lung cancer (NSCLC), in being tested for EGFR mutations, leaving some without access to the most appropriate treatment for them.

U.S. Food and Drug Administration granted approval for Empliciti (elotuzumab) in combination with two other therapies to treat people with multiple myeloma who have received one to three prior medications.

[adsense:336x280:8701650588]

 India's first injectible inactivated polio vaccine (IPV) was on Monday launched by Health Minister J.P. Nadda as part of the country's commitment to global polio eradication.

The European Commission has approved Boehringer Ingelheim's Praxbind (idarucizumab), a treatment to rapidly and specifically reverse the anticoagulant effects of Pradaxa (dabigatran etexilate) in cases of emergency surgery /urgent procedures or in situations of life-threatening or uncontrolled bleeding. Idarucizumab is the first specific reversal agent for a non-vitamin K antagonist oral anticoagulant (NOAC) to be approved in the European Union.

Mylan N.V.  announced the U.S. launch of Clozapine Orally Disintegrating Tablets, 25 mg and 100 mg, the generic version of Jazz Pharmaceutical's FazaClo®. Mylan received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for this product, which is used for the treatment of severely ill patients with schizophrenia who fail to respond adequately to standard antipsychotic treatment.